rsp
01.10.2007, 21:16
New 300-mg clopidogrel tablet approved
October 1, 2007Sue Hughes ([Ссылки могут видеть только зарегистрированные и активированные пользователи])
Bridgewater/Princeton, NJ - The US FDA has approved a new 300-mg tablet of clopidogrel (Plavix, Sanofi-aventis/Bristol-Myers Squibb) for use as a loading dose in acute coronary syndrome (ACS) patients.
In a Sanofi-aventis/BMS press release, Dr Marc Cohen (Newark Beth Israel Medical Center, NJ) points out that guidelines recommend a 300-mg loading dose of clopidogrel in conjunction with aspirin when ACS patients are first admitted to hospital, but that many appropriate ACS patients do not receive a loading dose of clopidogrel. The 300-mg loading dose has been proven effective in a broad ACS patient population, including those with unstable angina, non-ST-elevation MI, and ST-elevation MI, he added.
Clopidogrel is currently available as 75-mg tablets for chronic use. The 300-mg loading dose for ACS patients is already FDA approved, but must be administered as four 75-mg tablets. The new 300-mg tablet will thus simplify treatment.
October 1, 2007Sue Hughes ([Ссылки могут видеть только зарегистрированные и активированные пользователи])
Bridgewater/Princeton, NJ - The US FDA has approved a new 300-mg tablet of clopidogrel (Plavix, Sanofi-aventis/Bristol-Myers Squibb) for use as a loading dose in acute coronary syndrome (ACS) patients.
In a Sanofi-aventis/BMS press release, Dr Marc Cohen (Newark Beth Israel Medical Center, NJ) points out that guidelines recommend a 300-mg loading dose of clopidogrel in conjunction with aspirin when ACS patients are first admitted to hospital, but that many appropriate ACS patients do not receive a loading dose of clopidogrel. The 300-mg loading dose has been proven effective in a broad ACS patient population, including those with unstable angina, non-ST-elevation MI, and ST-elevation MI, he added.
Clopidogrel is currently available as 75-mg tablets for chronic use. The 300-mg loading dose for ACS patients is already FDA approved, but must be administered as four 75-mg tablets. The new 300-mg tablet will thus simplify treatment.